SURMOUNT Trial Results: What Tirzepatide Data Means

Last reviewed: June 4, 2026

Last updated: June 4, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

The SURMOUNT clinical trial program published landmark data showing tirzepatide produced weight reductions up to 22.5% over 72 weeks in adults with obesity or overweight with weight-related conditions. These pivotal studies established tirzepatide as a dual GLP-1 and GIP receptor agonist with measurable effects on appetite regulation and metabolic function. PlexusDx now offers compounded tirzepatide injections starting at $249 per month, bringing this evidence-backed therapy to patients across all 50 states without insurance requirements.

SURMOUNT Trial Design and Primary Outcomes

The SURMOUNT program consisted of three randomized, double-blind, placebo-controlled Phase 3 trials enrolling thousands of participants with body mass index of 30 or higher, or 27 or higher with weight-related conditions. Participants received weekly tirzepatide injections escalated to maintenance doses of 5, 10, or 15 milligrams, with the primary endpoint measuring weight change from baseline to week 72. The trials used identical protocols across diverse patient populations to establish the medication's effectiveness across different demographics and baseline health profiles.

Results showed dose-dependent weight loss, with the highest dose (15 mg weekly) producing an average reduction of 22.5% body weight compared to 2.4% in the placebo group. Notably, approximately 85% of patients taking the highest tirzepatide dose achieved weight loss of at least 5% of their starting weight, compared to just 26% in the placebo arm. These outcomes translated to average absolute weight reductions of 20-23 kilograms depending on the dose level, representing clinically meaningful changes in patient health trajectories.

Metabolic and Cardiometabolic Benefits Beyond Weight Loss

The SURMOUNT trials assessed secondary endpoints measuring improvements in blood sugar control, blood pressure, and lipid profiles alongside weight reduction. Participants demonstrated meaningful decreases in hemoglobin A1C levels, indicating better glucose regulation over time, and reductions in systolic blood pressure averaging 5-10 mmHg across treatment arms. These cardiometabolic improvements occurred independently of weight loss magnitude, suggesting tirzepatide's dual receptor mechanism provides metabolic benefits through multiple physiological pathways.

Triglyceride levels decreased substantially in trial participants, with some cohorts experiencing 20-30% reductions from baseline values. Total cholesterol and LDL cholesterol also trended favorably in tirzepatide-treated groups compared to placebo. These changes suggest potential cardiovascular risk reduction benefits, though long-term cardiovascular outcome studies continue to generate additional safety and efficacy data in real-world patient populations.

How Tirzepatide's Dual Mechanism Sets It Apart

Tirzepatide activates both GLP-1 and GIP receptors simultaneously, distinguishing it from single-agonist GLP-1 medications that target only the GLP-1 pathway. This dual action affects appetite centers in the brain more comprehensively while simultaneously improving insulin secretion and reducing hepatic glucose production. The synergistic effect of activating both pathways likely explains why SURMOUNT data showed superior weight loss compared to earlier single-agonist GLP-1 trials, establishing tirzepatide as a more potent appetite and metabolic regulator.

Individual genetic variation in GLP1R and GIPR receptor expression may influence how effectively patients respond to tirzepatide therapy. PlexusDx's Precision Peptide Genetic Test identifies variants in these receptor pathways, along with FTO and MC4R genes that affect appetite and metabolic regulation. Understanding your peptide-pathway genetics allows healthcare providers to optimize tirzepatide dosing strategies and predict treatment response likelihood before beginning therapy.

What SURMOUNT Data Means for PlexusDx Patients

PlexusDx delivers compounded tirzepatide injections from licensed 503A pharmacies, ensuring pharmaceutical-grade quality and potency based on the same active ingredient tested in SURMOUNT trials. Patients access tirzepatide starting at $249 monthly without requiring insurance approval, membership fees, or prior authorization delays. The monthly flat-rate pricing structure means dose escalation does not increase monthly costs, aligning with PlexusDx's commitment that your dose may need to go up, but your price won't.

SURMOUNT enrollment included diverse patient populations across age ranges, baseline weights, and metabolic profiles, demonstrating tirzepatide's applicability to varied clinical presentations. PlexusDx serves patients across all 50 states with medications HSA/FSA-eligible and no insurance requirement, removing geographic and financial barriers to accessing evidence-backed therapy. Adding the Precision Peptide Genetic Test for $99 after the first month of treatment provides personalized insight into your individual peptide-pathway response patterns, enabling more targeted treatment decisions informed by clinical trial data and your unique genetic profile.

Safety and Side Effect Profiles from SURMOUNT Evidence

Common side effects reported in SURMOUNT included nausea, vomiting, diarrhea, and constipation, typically occurring during dose escalation phases and often diminishing as patients adapted to treatment. Serious adverse events occurred at similar rates between tirzepatide and placebo groups, with no unexpected safety signals identified during the trial period. Dose-dependent gastrointestinal effects reflected tirzepatide's mechanism of action on appetite and digestion centers, usually managed through dietary adjustment and dose titration pacing.

Individual tolerability varies based on genetic factors affecting nausea-related neurotransmitter pathways and gastrointestinal motility genetics. PlexusDx's comprehensive peptide-pathway testing includes assessment of multiple genetic variants influencing medication tolerance and side effect susceptibility. This personalized approach helps predict which patients may experience mild versus moderate gastrointestinal effects, enabling proactive management strategies and informed shared decision-making before initiating compounded tirzepatide therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How much weight did patients lose in the SURMOUNT trials?

The highest tirzepatide dose (15 mg weekly) produced average weight loss of 22.5% body weight over 72 weeks, compared to 2.4% in placebo groups. Approximately 85% of patients on the maximum dose achieved at least 5% weight reduction, representing clinically significant metabolic improvement. PlexusDx patients receive the same active compound tes...

What makes tirzepatide different from other weight loss medications?

Tirzepatide activates both GLP-1 and GIP receptors simultaneously, providing dual-pathway appetite and metabolic regulation superior to single-agonist medications. SURMOUNT data demonstrated this dual mechanism produces greater weight loss and cardiometabolic improvements than earlier generation GLP-1 only therapies. This science-backed advantag...

How much does tirzepatide cost at PlexusDx?

PlexusDx compounded tirzepatide injection starts at $249 per month with a flat monthly rate across all three commitment tiers. Your dose may need to go up as treatment progresses, but your monthly price won't increase. The medication is HSA/FSA eligible, requires no insurance, and ships to all 50 states.

What side effects did SURMOUNT patients experience?

Common side effects included nausea, vomiting, diarrhea, and constipation, typically mild to moderate during dose escalation and often diminishing with time. Serious adverse events occurred at similar rates between tirzepatide and placebo groups. Individual side effect tolerance varies based on genetic factors related to gastrointestinal functio...

How does genetic testing improve tirzepatide outcomes?

PlexusDx's Precision Peptide Genetic Test ($99 add-on after month one) identifies variants in GLP1R, GIPR, FTO, and MC4R genes that influence appetite regulation and medication response. Understanding your peptide-pathway genetics helps predict tirzepatide effectiveness likelihood and potential side effect susceptibility, enabling personalized d...

The SURMOUNT Trials: What Tirzepatide’s Data Means for Patients